康艾注射液联合化疗治疗晚期非小细胞肺癌近期疗效

Short-term therapeutic effect of integrated Kang'ai injection and chemotherapy on patients with non-small cell lung cancer

目的观察中西医治疗Ⅲ、Ⅳ期非小细胞肺癌的近期疗效。方法将9r7例非小细胞肺癌患者随机分为2组,单纯化疗组46例,联合组51例。单纯化疗组采用长春瑞滨加顺铂(NP)方案,联合组化疗方案在单纯化疗基础上加用康艾注射液,治疗3个疗程后观察瘤体大小、卡氏评分、体重和不良反应发生情况。结果2组瘤体大小变化有效率分别为13.04%、21.57%,临床获益率分别为67.39%、74.51%,2组有效率比较,差异有统计学意义(P<0.05),但临床获益率比较差异无统计学意义(P>0.05)。单纯化疗组卡氏评分值下降,治疗前后比较,差异无统计学意义(P>0.05);联合组卡氏评分值上升,治疗前后比较,差异有统计学意义(P<0.05),治疗后组间比较差异有高度统计学意义(P<0.01)。2组治疗前后体重无明显变化(P>0.05)。联合组比单纯化疗组较少出现Ⅲ、Ⅳ度不良反应。Ⅲ度以上白细胞、血红蛋白下降和肝功能损害2组差异均有统计学意义(P<0.05),Ⅲ度以上血小板减少和恶心呕吐发生率2组间差异均无统计学意义(P>0.05)。结论康艾注射液联合化疗治疗中晚期非小细胞肺癌近期疗效优于单纯化疗组,不良反应较轻。

AIM To observe efficacy of integrated Kang＇ ai injection and chemotherapy on short-term therapeutic effect of patients with non-small cell lung cancer（NSCLC） in stage Ⅲ and Ⅳ. METHODS Adopting the prospective, randomized and controlled method for clinical research, 97 patients with NSCLC in stage Ⅲ and Ⅳ were randomly assigned into 2 groups. Fifty-one patients in the study group were given Kang＇ ai injection and chemotherapy（NVP or VDS ＋ DDP） ,46 patients in the control group were treated with chemotherapy（NVP or VDS ＋ DDP） alone. All 97 patients were treated in 3 too. The main observation indexes were tumor size, Kamofskv scores, body weight, adverse drug reaction, etc. RESULTS The total effective rates of tumor remission in the 2 groups were 13.04 % and 21.57 %. It showed significant difference between 2 groups （ P 〈 0.05）. The total tumor stabilization rates were 67.39 % and 74.5 %. No significant difference was shown between 2 groups（ P 〉 0.05）. After 3 too, the Karnofsky score in the study group raised than before, but it lowered in the control group. Paired t-test showed significant difference in the study group, and significant difference was also shown between 2 groups （ P 〈 0.01 ） after treatments. There was no significant difference shown in the control group before and after treatments. The patients＇ body weight in the 2 groups were all reduced, but there was no significant difference between 2 groups （ P 〉 0.05） ,and there was no significant difference in each group compared with the same group before treatment. Observation of adverse drug reaction showed that lesser hemotoxicity of grade Ⅲ and Ⅳ appeared in the study group than that in the control group, and significant difference was shown in counts of white blood cells, hemoglobin, but count of platelets showed no significant difference between 2 groups. The incidence of drug hepatitis show significant difference, but the incidence of nausea or vomit showed no significant difference between 2 groups.CONCLUSION The therapy integrated Kang＇ai injection and chemotherapy showed better short-term efficacy in treating patients with NSCLC than chemotherapy alone. It can improve quality of life of patients, reduce the adverse drug reaction of chemotherapy, and can be adopted as an effective therapeutic program with low-toxicity.